{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:43:55Z","timestamp":1790264635600,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Galectin-9 (Gal-9) expression can be negatively or positively associated with cancer patient prognosis, depending on the cancer type. However, the nature of this relationship remains unclear in multiple myeloma. Therefore, we evaluated the prognostic value of Gal-9 and its relationship with the expression of PD-L1 molecule, the most widely studied immune checkpoint inhibitor, in patients with newly diagnosed multiple myeloma. Gal-9 and PD-L1 levels in bone marrow aspirate samples were evaluated using immunofluorescence assays. Gal-9 positivity was defined as having \u22651% Gal-9-expressing plasma cells. PD-L1 expression was categorized as low or high based on its median value. The median OS of patients with positive and negative Gal-9 expression was 42 months and not reached, respectively. However, no significant difference was observed in OS between the two groups (<jats:italic>P =<\/jats:italic> 0.10). Patients with high PD-L1 expression had OS times of 14 and 43 months in the positive and negative Gal-9 expression groups, respectively. In the high PD-L1 expression group, patients expressing Gal-9 had significantly worse OS than those negative for it (<jats:italic>P<\/jats:italic> = 0.019). Multivariable Cox analysis confirmed that Gal-9 expression could independently predict shortened OS (hazard ratio, 1.090; 95% confidence interval, 1.015\u20131.171; <jats:italic>P<\/jats:italic> = 0.018) in patients with high PD-L1 expression. However, in the low PD-L1 expression group, patients with high Gal-9 expression exhibited a trend toward better OS (<jats:italic>P<\/jats:italic> = 0.816). Our results indicate that the prognostic value of Gal-9 may be related to PD-L1 expression in patients with newly diagnosed multiple myeloma.<\/jats:p>","DOI":"10.3389\/fonc.2021.669817","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T08:54:31Z","timestamp":1623660871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma"],"prefix":"10.3389","volume":"11","author":[{"given":"Byung-Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JI-Hea","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Won","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2013.04.006","article-title":"Galectin-9 in Tumor Biology: A Jack of Multiple Trades","volume":"1836","author":"Heusschen","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3978\/j.issn.2305-5839.2014.09.14","article-title":"Galectins as Therapeutic Targets for Hematological Malignancies: A Hopeful Sweetness","volume":"2","author":"Pena","year":"2014","journal-title":"Ann Transl Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s004320000207","article-title":"Comprehensive Galectin Fingerprinting in a Panel of 61 Human Tumor Cell Lines by RT-PCR and its Implications for Diagnostic and Therapeutic Procedures","volume":"127","author":"Lahm","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-04-0861","article-title":"Galectin-9 as a Prognostic Factor With Antimetastatic Potential in Breast Cancer","volume":"11","author":"Irie","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3347","article-title":"Galectin-9: An Anticancer Molecule for Gallbladder Carcinoma","volume":"48","author":"Tadokoro","year":"2016","journal-title":"Int J Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00432-008-0352-z","article-title":"Galectin-9 Expression Links to Malignant Potential of Cervical Squamous Cell Carcinoma","volume":"134","author":"Liang","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00452","article-title":"Galectin-9 Expression Predicts Favorable Clinical Outcome in Solid Tumors: A Systematic Review and Meta-Analysis","volume":"9","author":"Zhou","year":"2018","journal-title":"Front Physiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1159\/000487294","article-title":"Prognostic Role of High Gal-9 Expression in Solid Tumours: A Meta-Analysis","volume":"45","author":"Wang","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0152599","DOI":"10.1371\/journal.pone.0152599","article-title":"Reduced Expression of Galectin-9 Contributes to a Poor Outcome in Colon Cancer by Inhibiting Nk Cell Chemotaxis Partially Through the Rho\/ROCK1 Signaling Pathway","volume":"11","author":"Wang","year":"2016","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e81799","DOI":"10.1371\/journal.pone.0081799","article-title":"Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer","volume":"8","author":"Jiang","year":"2013","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020430","article-title":"Role of Galectins in Tumors and in Clinical Immunotherapy","volume":"19","author":"Chou","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ni1271","article-title":"The Tim-3 Ligand Galectin-9 Negatively Regulates T Helper Type 1 Immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01594","article-title":"The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer","volume":"10","author":"Yasinska","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700575","article-title":"Regulatory T Cell-Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9","volume":"199","author":"Madireddi","year":"2017","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1075-122X.2006.00334.x","article-title":"Galectin-9, A Novel Prognostic Factor With Antimetastatic Potential in Breast Cancer","volume":"12","author":"Yamauchi","year":"2006","journal-title":"Breast J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1273309","DOI":"10.1080\/2162402X.2016.1273309","article-title":"PD-L1, Galectin-9 and CD8(+) Tumor-Infiltrating Lymphocytes Are Associated With Survival in Hepatocellular Carcinoma","volume":"6","author":"Sideras","year":"2017","journal-title":"Oncoimmunology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3248-y","article-title":"Galectin-9 Predicts Postoperative Recurrence and Survival of Patients With Clear-Cell Renal Cell Carcinoma","volume":"36","author":"Fu","year":"2015","journal-title":"Tumour Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2018.05.18","article-title":"Galectin-9 as a Prognostic Biomarker in Small Cell Lung Cancer","volume":"7","author":"Xu","year":"2018","journal-title":"Trans Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40425-019-0611-3","article-title":"Gal9\/Tim-3 Expression Level Is Higher in AML Patients Who Fail Chemotherapy","volume":"7","author":"Dama","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S124321","article-title":"Serum Galectin-1 in Patients With Multiple Myeloma: Associations With Survival, Angiogenesis, and Biomarkers of Macrophage Activation","volume":"10","author":"Andersen","year":"2017","journal-title":"Onco Targets Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cww066","article-title":"Galectin-8 Enhances Adhesion of Multiple Myeloma Cells to Vascular Endothelium and Is an Adverse Prognostic Factor","volume":"26","author":"Friedel","year":"2016","journal-title":"Glycobiology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.137","article-title":"Galectin-1 Suppression Delineates a New Strategy to Inhibit Myeloma-Induced Angiogenesis and Tumoral Growth In Vivo","volume":"30","author":"Storti","year":"2016","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 Axis in Multiple Myeloma: A Dream or a Reality","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-018-0589-1","article-title":"Modulating PD-L1 Expression in Multiple Myeloma: An Alternative Strategy to Target the PD-1\/PD-L1 Pathway","volume":"11","author":"Tremblay-LeMay","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e6369","DOI":"10.1097\/MD.0000000000006369","article-title":"Prognostic Significance of PD-L1 in Solid Tumor: An Updated Meta-Analysis","volume":"96","author":"Wang","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of Programmed Cell Death Ligand 1 Is Associated With Poor Overall Survival in Patients With Diffuse Large B-Cell Lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 Inhibitors in Multiple Myeloma","volume":"9","author":"Jelinek","year":"2018","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0266","article-title":"Survival of Lung Adenocarcinoma Patients Predicted From Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells","volume":"4","author":"Ohue","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10677","DOI":"10.1038\/s41598-019-47235-z","article-title":"Circulating Levels of PD-L1 and Galectin-9 Are Associated With Patient Survival in Surgically Treated Hepatocellular Carcinoma Independent of Their Intra-Tumoral Expression Levels","volume":"9","author":"Sideras","year":"2019","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_159009","article-title":"Updated Diagnostic Criteria and Staging System for Multiple Myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B31","doi-asserted-by":"publisher","first-page":"12641","DOI":"10.1038\/s41598-020-69616-5","article-title":"Pd-L1 Expression in Bone Marrow Plasma Cells as a Biomarker to Predict Multiple Myeloma Prognosis: Developing a Nomogram-Based Prognostic Model","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122740","article-title":"Role of Galectins in Multiple Myeloma","volume":"18","author":"Storti","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.11.7660","article-title":"Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity Via Galectin-9-Tim-3 Interactions","volume":"181","author":"Nagahara","year":"2008","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01719","article-title":"T Cell Dysfunction in Cancer Immunity and Immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.clim.2011.11.006","article-title":"Galectin-9 Signaling Prolongs Survival in Murine Lung-Cancer by Inducing Macrophages to Differentiate Into Plasmacytoid Dendritic Cell-Like Macrophages","volume":"142","author":"Kadowaki","year":"2012","journal-title":"Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.25","article-title":"Galectin-9 Exhibits Anti-Myeloma Activity Through JNK and P38 Map Kinase Pathways","volume":"24","author":"Kobayashi","year":"2010","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.669817\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T08:54:34Z","timestamp":1623660874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.669817\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":36,"alternative-id":["10.3389\/fonc.2021.669817"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.669817","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"article-number":"669817"}}